Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 9Urinary Bladder Neoplasms 1Resectable HER2-positive Breast Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplastic Cells, Circulating 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1HR-positive,HER2-negative Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-negative Early Breast Cancer 1HER2-negative Breast Cancer 1HER2 Positive Early Breast Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Adenoid Cystic 1

Interventions

Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-negative Early Breast Cancer × Epirubicin × Clear all
NCT04836156 2022-04-06

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Peking University People's Hospital

Phase 1/2 Recruiting
46 enrolled
Breast

HER2-negative Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡